Which States Can You Get Compounded GLP-1s Shipped To in 2026?
Most U.S. adults can still receive patient-specific compounded semaglutide or tirzepatide by mail, but five states layer on extra board rules that make access harder-not impossible. Use this guide to see if your state is “open,” “restricted,” or “offline” before you request a prescription.
As of October 2026, a licensed 503A compounding pharmacy can legally ship compounded GLP-1 medications such as semaglutide or tirzepatide to residents of 46 states and Washington, DC, provided the pharmacy also holds a non-resident license in the destination state and fills a patient-specific prescription. Only Mississippi currently bars routine weight-loss prescribing of compounded GLP-1s, while Alabama, California, Kentucky, Ohio, and Oregon require extra documentation or licensure steps that many online clinics do not yet meet. If you live in one of those five “restricted” states, you can still receive medicine-but you must use a provider–pharmacy pair that satisfies the added board rules.
- 46 U.S. states plus DC accept interstate shipment of compounded GLP-1s when the pharmacy holds an active non-resident permit and fills a patient-specific prescription.(fda.gov)
- Mississippi’s medical board prohibits compounded semaglutide or tirzepatide for routine weight loss, effectively blocking shipments there.(msbml.ms.gov)
- Alabama bars use of non-pharmaceutical-grade semaglutide API and requires extra physician documentation, limiting pharmacy options.(albme.gov)
- California now demands every non-resident pharmacy name a California-licensed pharmacist-in-charge, effective July 1, 2026.(pharmacy.ca.gov)
- Most online GLP-1 programs list “can’t ship to AL, CA, KY, MS, OR, or OH” because their partner pharmacies are not yet licensed in those states-not because dispensing is universally illegal there.
What a Compounded GLP-1 Is and Why It Exists
Compounded GLP-1s are custom-made versions of injectable weight-loss drugs like Ozempic, Wegovy, Mounjaro, or Zepbound that a 503A pharmacy mixes for one named patient when the commercial product is not available or not suitable. Under section 503A of the Food, Drug, and Cosmetic Act, a state-licensed pharmacist or physician may compound a drug after receiving a valid prescription that specifies the patient and clinical need. The FDA’s 2026 clarification reminds compounders they cannot make “essentially a copy” of an in-stock drug unless the drug is on the shortage list or the prescriber documents a specific difference for the patient.(fda.gov)
Shortages opened the door: Both semaglutide and tirzepatide spent most of 2023–2025 on FDA’s drug-shortage list, so thousands of patients turned to compounded versions. Although FDA declared the shortages “resolved” in 2025, it is exercising limited enforcement discretion until at least March 2027 for outsourcing facilities and traditional pharmacies that follow strict rules.(fda.gov)
How Interstate Pharmacy Shipping Works
A pharmacy must hold a non-resident license in every state it ships to, and many boards also require a specific sterile-compounding endorsement. If a telehealth clinic says it “can’t ship” to your state, it usually means its partner pharmacy lacks that license, not that the state outlaws compounded GLP-1s.
Key checkpoints:
- Non-resident pharmacy permit: Granted by the destination state’s board of pharmacy.
- USP <797> compliance: Sterile injectables must meet the 2023 revised standards adopted by nearly all states.(pharmacy.ohio.gov)
- Pharmacist-in-charge (PIC): California now requires a California-licensed PIC for any out-of-state pharmacy shipping into the state.(pharmacy.ca.gov)
- Patient-specific prescription (no office stock): 503A pharmacies may not bulk compound for resale.
Which States Add Extra Hurdles in 2026
Only one state-Mississippi-currently blocks routine weight-loss prescribing of compounded GLP-1s outright. Five additional states impose special documentation, ingredient, or licensure requirements that many online programs have not yet met.
Mississippi: The state medical board’s 2024 supplemental guidance denies a blanket waiver for compounded semaglutide for weight loss, meaning prescribers cannot routinely order it.(msbml.ms.gov)
Alabama: The Board of Medical Examiners warns that using non-pharmaceutical-grade semaglutide API or semaglutide salts is prohibited, and it notes no in-state pharmacy currently stocks compliant API.(albme.gov)
California: Effective July 1, 2026, every non-resident pharmacy must designate a California-licensed PIC and comply with new quarterly reporting, increasing the cost and paperwork of shipping into the state.(pharmacy.ca.gov)
Oregon: The Board of Pharmacy adopted a 2025 position statement requiring prescribers to document why an FDA-approved GLP-1 does not meet the patient’s needs before ordering a compounded version.(oregon.gov)
Ohio & Kentucky: Both boards published 2025 guidance that echoes FDA’s “no copy” rule and warns pharmacies they may face enforcement if they dispense large volumes without clear medical necessity.(pharmacy.ohio.gov)
State-by-State Availability Table
The table below summarizes where a properly licensed 503A pharmacy can ship compounded GLP-1s as of October 2026. “Yes” means routine shipment is feasible; “Restricted” means extra board rules apply; “No” means routine weight-loss shipping is effectively unavailable.
| State | Shipments Allowed? | Notes |
|---|---|---|
| Alabama | Restricted | API grade & physician documentation rules.(albme.gov) |
| Alaska | Yes | No unique board guidance. |
| Arizona | Yes | No unique board guidance. |
| Arkansas | Yes | No unique board guidance. |
| California | Restricted | Non-resident PIC requirement effective 7/1/2026.(pharmacy.ca.gov) |
| Colorado | Yes | No unique board guidance. |
| Connecticut | Yes | Board issued warning letter but no restrictions. |
| Delaware | Yes | No unique board guidance. |
| District of Columbia | Yes | No unique board guidance. |
| Florida | Yes | No unique board guidance. |
| Georgia | Yes | No unique board guidance. |
| Hawaii | Yes | Island shipment permitted if cold-chain validated. |
| Idaho | Yes | No unique board guidance. |
| Illinois | Yes | No unique board guidance. |
| Indiana | Yes | No unique board guidance. |
| Iowa | Yes | No unique board guidance. |
| Kansas | Yes | No unique board guidance. |
| Kentucky | Restricted | Board guidance requires documented clinical difference.(pharmacy.ky.gov) |
| Louisiana | Yes* | *Additional non-resident sterile-compounding inspection reports required.(pharmacy.la.gov) |
| Maine | Yes | No unique board guidance. |
| Maryland | Yes | No unique board guidance. |
| Massachusetts | Yes | No unique board guidance. |
| Michigan | Yes | No unique board guidance. |
| Minnesota | Yes | No unique board guidance. |
| Mississippi | No | Board bars routine weight-loss use.(msbml.ms.gov) |
| Missouri | Yes | No unique board guidance. |
| Montana | Yes | No unique board guidance. |
| Nebraska | Yes | No unique board guidance. |
| Nevada | Yes | No unique board guidance. |
| New Hampshire | Yes | No unique board guidance. |
| New Jersey | Yes | No unique board guidance. |
| New Mexico | Yes | No unique board guidance. |
| New York | Yes* | *High inspection standards; pharmacy must file annual GMP report. |
| North Carolina | Yes | No unique board guidance. |
| North Dakota | Yes* | *Requires VPP or equivalent inspection for sterile compounding.(legis.nd.gov) |
| Ohio | Restricted | Board guidance on “no-copy” and volume limits.(pharmacy.ohio.gov) |
| Oklahoma | Yes | No unique board guidance. |
| Oregon | Restricted | 2025 semaglutide position statement.(oregon.gov) |
| Pennsylvania | Yes | No unique board guidance. |
| Rhode Island | Yes | No unique board guidance. |
| South Carolina | Yes | No unique board guidance. |
| South Dakota | Yes | No unique board guidance. |
| Tennessee | Yes | No unique board guidance. |
| Texas | Yes | No unique board guidance. |
| Utah | Yes | No unique board guidance. |
| Vermont | Yes | No unique board guidance. |
| Virginia | Yes | No unique board guidance. |
| Washington | Yes | No unique board guidance. |
| West Virginia | Yes | No unique board guidance. |
| Wisconsin | Yes | No unique board guidance. |
| Wyoming | Yes | No unique board guidance. |
How to Check a Pharmacy License in 60 Seconds
You can verify any pharmacy’s non-resident permit online through your state board’s lookup tool or NABP’s e-Profile. For example, the California Board lists 593 active non-resident pharmacy licenses as of Q3 2026.(pharmacy.ca.gov)
Steps:
- Find your board’s license verification page (Google “[state] pharmacy license lookup”).
- Enter the pharmacy’s name or NABP number.
- Confirm the status is “Active” and that “Sterile Compounding” is listed under services.
Is an online compounded GLP-1 program right for me?
Check the column that fits your situation:
✅ Probably safe to proceed
- You live in a “Yes” or “Restricted” state and can verify the pharmacy’s license
- Your BMI is 30 kg/m² or higher (or 27 kg/m² with a weight-related condition)
- You can self-inject or have caregiver support
- No history of medullary thyroid carcinoma or multiple endocrine neoplasia 2
🏥 Talk to a clinician first
- You live in Mississippi
- Pregnant, breastfeeding, or planning pregnancy
- Severe gastrointestinal disease or pancreatitis history
- Unable to afford lab monitoring or follow-up visits
- Uncontrolled thyroid nodules or elevated calcitonin
Cost and Insurance: What to Expect in 2026
Compounded semaglutide averages $200–$350 per month at many clinics, but Rx.com’s program starts at $99 per month for compounded semaglutide and $149 for compounded tirzepatide with a 12-month plan. The price includes the online visit, medication at any dose, and shipping, and you are not charged for medication if the provider does not approve treatment.
Brand-name GLP-1s (Wegovy, Zepbound) list for $936–$1,349 per four-week supply, but manufacturer savings cards can lower the cost to $0–$25 per month for commercially insured patients who meet the criteria. Always compare cash prices at local pharmacies with a free Rx.com prescription discount card if you plan to pay out of pocket.
| Product | Typical cash price (4 weeks) | Rx.com program price |
|---|---|---|
| Brand Wegovy 2.4 mg | $1,349 (NovoCare list) | N/A (brand not sold cash) |
| Compounded semaglutide | $200–$350 (various boards’ price filings) | $99 /month* |
| Compounded tirzepatide | $300–$450 (various boards’ price filings) | $149 /month* |
*12-month prepaid plan. Includes provider visit, any dose, supplies, and shipping.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following:
- Persistent severe nausea or vomiting - risk of dehydration and electrolyte imbalance
- Abdominal pain radiating to the back - could signal pancreatitis
- Vision changes - rare reports of diabetic retinopathy complications
- Rapid heartbeat or dizziness - may indicate dehydration or hypoglycemia
- Swelling of face, lips, or throat - possible allergic reaction
- Lump or swelling in the neck - evaluate for thyroid issues
- Thoughts of self-harm or depression - call or text 988 if you feel unsafe
Scientific References
- FDA. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2026.
- Mississippi State Board of Medical Licensure. Supplemental Guidance Regarding GLP-1 and GIP Medications. 2024.
- Alabama Board of Medical Examiners. Concerns With Semaglutide and Other GLP-1 Receptor Agonists. 2025.
- California Board of Pharmacy. New Requirements for Nonresident Pharmacies. 2026.
- Ohio Board of Pharmacy. Guidance on Compounding of GLP-1 Drug Products. 2025.
- Oregon Board of Pharmacy. Semaglutide Position Statement. 2025.
Frequently Asked Questions
Does the FDA ban compounded semaglutide now that shortages are over?
No. FDA ended its official shortage listing in 2025 but is using “enforcement discretion” until at least 2027. Pharmacies may still compound semaglutide if they follow 503A rules and document a patient-specific need.(fda.gov)
Why do many telehealth sites say they cannot ship to California?
California’s July 2026 law forces every out-of-state pharmacy to name a California-licensed pharmacist-in-charge and meet stricter quarterly reporting. Many partner pharmacies are still completing that paperwork, so clinics temporarily pause California orders.(pharmacy.ca.gov)
Can my local compounding pharmacy make semaglutide if Ozempic is in stock?
Only if your prescriber documents a specific difference-such as a required lower dose, an excipient allergy, or a B12 co-formulation-that the commercial pen cannot meet. Otherwise, compounding a “copy” is prohibited.(fda.gov)
Is compounded tirzepatide the same as Zepbound?
No. Compounded tirzepatide is not FDA-approved, and its safety and effectiveness have not been reviewed by the agency. It should not be considered therapeutically equivalent to Zepbound or Mounjaro.
What temperature controls are required during shipping?
Most boards follow USP <1079> for cold-chain drugs, meaning semaglutide or tirzepatide must stay between 36 °F and 46 °F until the patient receives it. Pharmacies use validated coolers with temperature indicators.
Will insurance pay for a compounded GLP-1?
Usually not. Commercial plans rarely cover compounded copies of brand drugs. If your insurer covers Wegovy or Zepbound, using the brand is almost always cheaper after co-pay cards.
Can compounded GLP-1s be refilled automatically?
Yes, but only if each refill corresponds to a new patient-specific prescription or authorized refill. Pharmacies cannot bulk-ship without an active prescription on file.
